WO2011099764A3 - Novel pyrimidine derivative for inhibiting the growth of cancer cells - Google Patents

Novel pyrimidine derivative for inhibiting the growth of cancer cells Download PDF

Info

Publication number
WO2011099764A3
WO2011099764A3 PCT/KR2011/000858 KR2011000858W WO2011099764A3 WO 2011099764 A3 WO2011099764 A3 WO 2011099764A3 KR 2011000858 W KR2011000858 W KR 2011000858W WO 2011099764 A3 WO2011099764 A3 WO 2011099764A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth
cancer cells
pyrimidine derivative
inhibiting
novel pyrimidine
Prior art date
Application number
PCT/KR2011/000858
Other languages
French (fr)
Other versions
WO2011099764A2 (en
Inventor
Mi Young Cha
Mi Ra Kim
Seok Jong Kang
Se Young Kim
Young Hee Jung
Kwang Ok Lee
Ji Yeon Song
Young Hoon Kim
Eun Young Kim
Maeng Sup Kim
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Publication of WO2011099764A2 publication Critical patent/WO2011099764A2/en
Publication of WO2011099764A3 publication Critical patent/WO2011099764A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The present invention provides a novel pyrimidine derivative or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, which can effectively inhibit the growth of cancer cells induced by the overexpression of EGFR including subtypes and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase including subtypes.
PCT/KR2011/000858 2010-02-09 2011-02-09 Novel pyrimidine derivative for inhibiting the growth of cancer cells WO2011099764A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100011979A KR101301533B1 (en) 2010-02-09 2010-02-09 Novel pyrimidine derivatives for inhibiting cancer cell growth
KR10-2010-0011979 2010-02-09

Publications (2)

Publication Number Publication Date
WO2011099764A2 WO2011099764A2 (en) 2011-08-18
WO2011099764A3 true WO2011099764A3 (en) 2012-01-05

Family

ID=44368289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000858 WO2011099764A2 (en) 2010-02-09 2011-02-09 Novel pyrimidine derivative for inhibiting the growth of cancer cells

Country Status (2)

Country Link
KR (1) KR101301533B1 (en)
WO (1) WO2011099764A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529800A (en) * 2014-12-08 2015-04-22 重庆威鹏药业有限公司 Preparation method of trans-4-dimethylaminocrotonic acid and its salt

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059230T2 (en) 2011-06-10 2022-10-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CA2917667A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2016325143B2 (en) * 2015-09-18 2020-08-13 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
RS64908B1 (en) 2015-11-17 2023-12-29 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
EP3426637B1 (en) 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Compounds and methods for modulating bruton's tyrosine kinase
JP6469272B2 (en) * 2017-03-01 2019-02-13 科研製薬株式会社 A pharmaceutical comprising a biaryl derivative or a salt thereof
TWI809967B (en) * 2021-07-06 2023-07-21 石 全 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132822A1 (en) * 2000-10-26 2002-09-19 Noe Mark C. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US20070270421A1 (en) * 2004-02-27 2007-11-22 Tomohiro Matsushima Novel pyridine Derivative and Pyrimidine Derivative (1)
US20090227587A1 (en) * 2003-10-31 2009-09-10 Warner-Lambert Company Llc Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070712A1 (en) 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132822A1 (en) * 2000-10-26 2002-09-19 Noe Mark C. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US20090227587A1 (en) * 2003-10-31 2009-09-10 Warner-Lambert Company Llc Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K)
US20070270421A1 (en) * 2004-02-27 2007-11-22 Tomohiro Matsushima Novel pyridine Derivative and Pyrimidine Derivative (1)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529800A (en) * 2014-12-08 2015-04-22 重庆威鹏药业有限公司 Preparation method of trans-4-dimethylaminocrotonic acid and its salt
CN104529800B (en) * 2014-12-08 2017-01-25 重庆威鹏药业有限公司 Preparation method of trans-4-dimethylaminocrotonic acid and its salt

Also Published As

Publication number Publication date
KR101301533B1 (en) 2013-09-04
WO2011099764A2 (en) 2011-08-18
KR20110092517A (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
WO2008150118A3 (en) Novel amide derivative for inhibiting the growth of cancer cells
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2014011900A3 (en) Inhibitors of the fibroblast growth factor receptor
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
MY174196A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
IN2012DN02577A (en)
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX367795B (en) Cdk inhibitors.
TN2011000293A1 (en) Protein kinase inhibitors
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
AP2012006166A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors.
WO2010108074A3 (en) Inhibitors of pi3 kinase
EA023222B8 (en) Pyrazolyl quinazoline kinase inhibitors
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX356644B (en) 2-phenylaminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease.
WO2012106522A3 (en) Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013004995A8 (en) Pyrimidinone compounds and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742456

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11742456

Country of ref document: EP

Kind code of ref document: A2